A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- Registration Number
- NCT04009499
- Lead Sponsor
- UCB Biopharma SRL
- Brief Summary
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1131
- In the opinion of the Investigator, the subject is expected to benefit from participation in this Open-Label Extension study
- Subject completed PA0010 [NCT03895203] or PA0011 [NCT03896581] without meeting any withdrawal criteria
- Female subjects must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception
- Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of investigational medicinal product (IMP)
- Subjects who meet any withdrawal criteria in PA0010 or PA0011. For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder studies, the Medical Monitor must be consulted prior to the subject's entry into PA0012, although the decision to enroll the subject remains with the Investigator
- Subject has a positive or 2 indeterminate interferon gamma release assays (IGRAs) in one of the feeder studies, unless appropriately evaluated and treated
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Bimekzumab dosage regimen Bimekizumab Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.
- Primary Outcome Measures
Name Time Method Incidence of treatment-emergent adverse events (TEAEs) during the study From PA0012 Entry Visit until Safety Follow-Up (up to Week 212) An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Incidence of treatment-emergent serious adverse events (SAEs) during the study From PA0012 Entry Visit until Safety Follow-Up (up to Week 212) A serious adverse event (SAE) is any untoward medical occurrence that at any dose:
* Results in death
* Is life-threatening
* Requires in patient hospitalization or prolongation of existing hospitalization
* Is a congenital anomaly or birth defect
* Is an infection that requires treatment parenteral antibiotics
* Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above
- Secondary Outcome Measures
Name Time Method American College of Rheumatology 20% improvement (ACR20) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 The ACR20 response rate is based on a 20% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
American College of Rheumatology 50% improvement (ACR50) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 The ACR50 response rate is based on a 50% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
American College of Rheumatology 50% improvement (ACR50) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 The ACR50 response rate is based on a 50% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
Enthesitis-free state based on the Leeds Enthesitis Index (LEI) at Week 140 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 Presence of enthesitis will be assessed in the subgroup of subjects with enthesitis by palpation on the lateral epicondyles of the humerus (elbows), medial femoral epicondyles (knees), and Achilles tendons (heels) bilaterally and scored as 0=no pain and 1=painful at Baseline of PA0010 or PA0011.
American College of Rheumatology 70% improvement (ACR70) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 The ACR70 response rate is based on a 70% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
American College of Rheumatology 20% improvement (ACR20) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 The ACR20 response rate is based on a 20% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
American College of Rheumatology 70% improvement (ACR70) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 The ACR70 response rate is based on a 70% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
Psoriasis Area Severity Index 90 (PASI90) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 The PASI will be assessed for the purposes of determining response only in subjects with psoriasis (PSO) involving at ≥3% of body surface area (BSA) at Baseline of PA0010 or PA0011.
The PASI90 response is based on at least 90% improvement in the PASI score compared to Baseline of of PA0010 or PA0011.
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5-point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.Dactylitis-free state based on the Leeds Dactylitis Index (LDI) at Week 24 in PA0012 using the subgroup of subjects with dactylitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 Presence of dactylitis will be assessed in the subgroup of subjects with dactylitis using the LDI basic which evaluates for a \>=10% difference in the circumference of the digit compared to the opposite digit this is then multiplied by the tenderness score, using a simple grading system (0=absent, 1=present) at Baseline of PA0010 or PA0011.
Dactylitis-free state based on the Leeds Dactylitis Index (LDI) at Week 140 in PA0012 using the subgroup of subjects with dactylitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 Presence of dactylitis will be assessed in the subgroup of subjects with dactylitis using the LDI basic which evaluates for a \>=10% difference in the circumference of the digit compared to the opposite digit this is then multiplied by the tenderness score, using a simple grading system (0=absent, 1=present) at Baseline of PA0010 or PA0011.
TEAEs leading to withdrawal from investigational medicinal product (IMP) during the study From PA0012 Entry Visit until Safety Follow-Up (up to Week 212) An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
American College of Rheumatology 20% improvement (ACR20) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 The ACR20 response rate is based on a 20% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
American College of Rheumatology 50% improvement (ACR50) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 The ACR50 response rate is based on a 50% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
Enthesitis-free state based on the Spondyloarthritis Research Consortium of Canada (SPARCC) index at Week 52 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 Presence of enthesitis will be assessed in the subgroup of subjects with enthesitis at Baseline of PA0010 or PA0011. The Spondyloarthritis Research Consortium of Canada (SPARCC) is an index that measures the severity of enthesitis through the assessment of 16 sites. Tenderness on examination is recorded as either present (1) or absent (0) for each of the 16 sites, for an overall score range of 0 to 16.
American College of Rheumatology 70% improvement (ACR70) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 The ACR70 response rate is based on a 70% or greater improvement of arthritis relative to Baseline of PA0010 or PA0011.
Psoriasis Area Severity Index 90 (PASI90) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 The PASI will be assessed for the purposes of determining response only in subjects with psoriasis (PSO) involving at ≥3% of body surface area (BSA) at Baseline of PA0010 or PA0011.
The PASI90 response is based on at least 90% improvement in the PASI score compared to Baseline of of PA0010 or PA0011.
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5-point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.Psoriasis Area Severity Index 90 (PASI90) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 The PASI will be assessed for the purposes of determining response only in subjects with psoriasis (PSO) involving at ≥3% of body surface area (BSA) at Baseline of PA0010 or PA0011.
The PASI90 response is based on at least 90% improvement in the PASI score compared to Baseline of of PA0010 or PA0011.
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5-point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) AND at least a 2-grade reduction at Week 24 from the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 A static Investigator Global Assessment (IGA) for psoriasis (PSO) will be used to assess disease severity during the study only for subjects with IGA ≥2 at the Baseline of PA0010 or PA0011.
An IGA response is defined as Clear or Almost Clear with at least a 2-category improvement relative to Baseline of PA0010 or PA0011.Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) AND at least a 2-grade reduction at Week 52 from the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 A static Investigator Global Assessment (IGA) for psoriasis (PSO) will be used to assess disease severity during the study only for subjects with IGA ≥2 at the Baseline of PA0010 or PA0011.
An IGA response is defined as Clear or Almost Clear with at least a 2-category improvement relative to Baseline of PA0010 or PA0011.Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) AND at least a 2-grade reduction at Week 140 from the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 A static Investigator Global Assessment (IGA) for psoriasis (PSO) will be used to assess disease severity during the study only for subjects with IGA ≥2 at the Baseline of PA0010 or PA0011.
An IGA response is defined as Clear or Almost Clear with at least a 2-category improvement relative to Baseline of PA0010 or PA0011Enthesitis-free state based on the Leeds Enthesitis Index (LEI) at Week 24 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 Presence of enthesitis will be assessed in the subgroup of subjects with enthesitis by palpation on the lateral epicondyles of the humerus (elbows), medial femoral epicondyles (knees), and Achilles tendons (heels) bilaterally and scored as 0=no pain and 1=painful at Baseline of PA0010 or PA0011.
Psoriasis Area Severity Index 75 (PASI75) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 The PASI will be assessed for the purposes of determining response only in subjects with psoriasis (PSO) involving at ≥3% of body surface area (BSA) at Baseline of PA0010 or PA0011.
The PASI75 response is based on at least 75% improvement in the PASI score compared to Baseline of of PA0010 or PA0011.
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5-point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.Psoriasis Area Severity Index 75 (PASI75) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 The PASI will be assessed for the purposes of determining response only in subjects with psoriasis (PSO) involving at ≥3% of body surface area (BSA) at Baseline of PA0010 or PA0011.
The PASI75 response is based on at least 75% improvement in the PASI score compared to Baseline of of PA0010 or PA0011.
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5-point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.Psoriasis Area Severity Index 75 (PASI75) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 The PASI will be assessed for the purposes of determining response only in subjects with psoriasis (PSO) involving at ≥3% of body surface area (BSA) at Baseline of PA0010 or PA0011.
The PASI75 response is based on at least 75% improvement in the PASI score compared to Baseline of of PA0010 or PA0011.
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body area (each on a 5-point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.Enthesitis-free state based on the Spondyloarthritis Research Consortium of Canada (SPARCC) index at Week 24 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 24 in PA0012 Presence of enthesitis will be assessed in the subgroup of subjects with enthesitis at Baseline of PA0010 or PA0011. The Spondyloarthritis Research Consortium of Canada (SPARCC) is an index that measures the severity of enthesitis through the assessment of 16 sites. Tenderness on examination is recorded as either present (1) or absent (0) for each of the 16 sites, for an overall score range of 0 to 16.
Enthesitis-free state based on the Spondyloarthritis Research Consortium of Canada (SPARCC) index at Week 140 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 140 in PA0012 Presence of enthesitis will be assessed in the subgroup of subjects with enthesitis at Baseline of PA0010 or PA0011. The Spondyloarthritis Research Consortium of Canada (SPARCC) is an index that measures the severity of enthesitis through the assessment of 16 sites. Tenderness on examination is recorded as either present (1) or absent (0) for each of the 16 sites, for an overall score range of 0 to 16.
Dactylitis-free state based on the Leeds Dactylitis Index (LDI) at Week 52 in PA0012 using the subgroup of subjects with dactylitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 Presence of dactylitis will be assessed in the subgroup of subjects with dactylitis using the LDI basic which evaluates for a \>=10% difference in the circumference of the digit compared to the opposite digit this is then multiplied by the tenderness score, using a simple grading system (0=absent, 1=present) at Baseline of PA0010 or PA0011.
Enthesitis-free state based on the Leeds Enthesitis Index (LEI) at Week 52 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011 Baseline of PA0010 or PA0011, Week 52 in PA0012 Presence of enthesitis will be assessed in the subgroup of subjects with enthesitis by palpation on the lateral epicondyles of the humerus (elbows), medial femoral epicondyles (knees), and Achilles tendons (heels) bilaterally and scored as 0=no pain and 1=painful at Baseline of PA0010 or PA0011.
Trial Locations
- Locations (139)
Pa0012 50017
🇺🇸Phoenix, Arizona, United States
Pa0012 50035
🇺🇸San Diego, California, United States
Pa0012 50033
🇺🇸Palm Harbor, Florida, United States
Pa0012 50037
🇺🇸Tampa, Florida, United States
Pa0012 50039
🇺🇸Atlanta, Georgia, United States
Pa0012 50024
🇺🇸Boise, Idaho, United States
Pa0012 50028
🇺🇸Lexington, Kentucky, United States
Pa0012 50023
🇺🇸Baton Rouge, Louisiana, United States
Pa0012 50015
🇺🇸Hagerstown, Maryland, United States
Pa0012 50026
🇺🇸Wheaton, Maryland, United States
Pa0012 50047
🇺🇸Boston, Massachusetts, United States
Pa0012 50019
🇺🇸Lansing, Michigan, United States
Pa0012 50016
🇺🇸Saint Louis, Missouri, United States
Pa0012 50005
🇺🇸Freehold, New Jersey, United States
Pa0012 50029
🇺🇸Albuquerque, New Mexico, United States
Pa0012 50010
🇺🇸Brooklyn, New York, United States
Pa0012 50011
🇺🇸New York, New York, United States
Pa0012 50034
🇺🇸Rochester, New York, United States
Pa0012 50125
🇺🇸Charlotte, North Carolina, United States
Pa0012 50031
🇺🇸Salisbury, North Carolina, United States
Pa0012 50040
🇺🇸Vandalia, Ohio, United States
Pa0012 50020
🇺🇸Duncansville, Pennsylvania, United States
Pa0012 50006
🇺🇸Wyomissing, Pennsylvania, United States
Pa0012 50008
🇺🇸Johnston, Rhode Island, United States
Pa0012 50007
🇺🇸Orangeburg, South Carolina, United States
Pa0012 50001
🇺🇸Jackson, Tennessee, United States
Pa0012 50012
🇺🇸Memphis, Tennessee, United States
Pa0012 50002
🇺🇸Austin, Texas, United States
Pa0012 50049
🇺🇸Corpus Christi, Texas, United States
Pa0012 50036
🇺🇸Mesquite, Texas, United States
Pa0012 50009
🇺🇸Waco, Texas, United States
Pa0012 50050
🇺🇸Beckley, West Virginia, United States
Pa0012 30005
🇦🇺Camberwell, Australia
Pa0012 30002
🇦🇺Clayton, Australia
Pa0012 30008
🇦🇺Hobart, Australia
Pa0012 30003
🇦🇺Maroochydore, Australia
Pa0012 30007
🇦🇺Victoria Park, Australia
Pa0012 30006
🇦🇺Woodville South, Australia
Pa0012 40003
🇧🇪Genk, Belgium
Pa0012 40002
🇧🇪Leuven, Belgium
Pa0012 40059
🇧🇪Mons, Belgium
Pa0012 50041
🇨🇦Quebec, Canada
Pa0012 50042
🇨🇦Rimouski, Canada
Pa0012 50043
🇨🇦Sydney, Canada
Pa0012 50044
🇨🇦Trois-rivieres, Canada
Pa0012 40061
🇨🇿Brno, Czechia
Pa0012 40065
🇨🇿Brno, Czechia
Pa0012 40062
🇨🇿Ostrava, Czechia
Pa0012 40009
🇨🇿Pardubice, Czechia
Pa0012 40013
🇨🇿Praha 11, Czechia
Pa0012 40066
🇨🇿Praha 2, Czechia
Pa0012 40014
🇨🇿Praha 4, Czechia
Pa0012 40063
🇨🇿Praha 5, Czechia
Pa0012 40015
🇨🇿Praha, Czechia
Pa0012 40010
🇨🇿Uherske Hradiste, Czechia
Pa0012 40012
🇨🇿Zlin, Czechia
Pa0012 40068
🇫🇷Chambray Les Tours, France
Pa0012 40019
🇫🇷Paris, France
Pa0012 40074
🇩🇪Bad Doberan, Germany
Pa0012 40025
🇩🇪Berlin, Germany
Pa0012 40076
🇩🇪Cottbus, Germany
Pa0012 40023
🇩🇪Erlangen, Germany
Pa0012 40117
🇩🇪Frankfurt, Germany
Pa0012 40029
🇩🇪Hamburg, Germany
Pa0012 40071
🇩🇪Hamburg, Germany
Pa0012 40027
🇩🇪Herne, Germany
Pa0012 40078
🇩🇪Leipzig, Germany
Pa0012 40026
🇩🇪Ratingen, Germany
Pa0012 40081
🇭🇺Budapest, Hungary
Pa0012 40083
🇭🇺Budapest, Hungary
Pa0012 40032
🇭🇺Debrecen, Hungary
Pa0012 40030
🇭🇺Eger, Hungary
Pa0012 40082
🇭🇺Kistarcsa, Hungary
Pa0012 40079
🇭🇺Szentes, Hungary
Pa0012 40033
🇭🇺Székesfehérvár, Hungary
Pa0012 40084
🇮🇹Catania, Italy
Pa0012 40087
🇮🇹Milano, Italy
Pa0012 40086
🇮🇹Reggio Emilia, Italy
Pa0012 20035
🇯🇵Bunkyo-ku, Japan
Pa0012 20030
🇯🇵Chuo-ku, Japan
Pa0012 20043
🇯🇵Itabashi-ku, Japan
Pa0012 20036
🇯🇵Kawachinagano, Japan
Pa0012 20045
🇯🇵Kita-gun, Japan
Pa0012 20049
🇯🇵Kitakyushu, Japan
Pa0012 20044
🇯🇵Minato-ku, Japan
Pa0012 20033
🇯🇵Nagoya, Japan
Pa0012 20041
🇯🇵Osaka, Japan
Pa0012 20046
🇯🇵Osaka, Japan
Pa0012 20048
🇯🇵Saitama, Japan
Pa0012 20031
🇯🇵Sapporo, Japan
Pa0012 20042
🇯🇵Sasebo, Japan
Pa0012 20032
🇯🇵Suita, Japan
Pa0012 40093
🇵🇱Bialystok, Poland
Pa0012 40119
🇵🇱Bydgoszcz, Poland
Pa0012 40038
🇵🇱Elblag, Poland
Pa0012 40088
🇵🇱Elblag, Poland
Pa0012 40096
🇵🇱Gdynia, Poland
Pa0012 40042
🇵🇱Krakow, Poland
Pa0012 40092
🇵🇱Kraków, Poland
Pa0012 40037
🇵🇱Lublin, Poland
Pa0012 40091
🇵🇱Nowa Sól, Poland
Pa0012 40044
🇵🇱Poznan, Poland
Pa0012 40090
🇵🇱Poznan, Poland
Pa0012 40118
🇵🇱Warsaw, Poland
Pa0012 40041
🇵🇱Warszawa, Poland
Pa0012 40094
🇵🇱Warszawa, Poland
Pa0012 40097
🇵🇱Warszawa, Poland
Pa0012 40098
🇵🇱Warszawa, Poland
Pa0012 40039
🇵🇱Wroclaw, Poland
Pa0012 40043
🇵🇱Wroclaw, Poland
Pa0012 40095
🇵🇱Wroclaw, Poland
Pa0012 20002
🇷🇺Moscow, Russian Federation
Pa0012 20005
🇷🇺Moscow, Russian Federation
Pa0012 20010
🇷🇺Moscow, Russian Federation
Pa0012 20017
🇷🇺Moscow, Russian Federation
Pa0012 20013
🇷🇺Petrozavodsk, Russian Federation
Pa0012 20012
🇷🇺Ryazan, Russian Federation
Pa0012 20016
🇷🇺Ryazan, Russian Federation
Pa0012 20004
🇷🇺Saint Petersburg, Russian Federation
Pa0012 20001
🇷🇺Saint-petersburg, Russian Federation
Pa0012 20003
🇷🇺Saint-petersburg, Russian Federation
Pa0012 20009
🇷🇺Saint-petersburg, Russian Federation
Pa0012 20083
🇷🇺Saint-petersburg, Russian Federation
Pa0012 20007
🇷🇺Saratov, Russian Federation
Pa0012 20014
🇷🇺Ulyanovsk, Russian Federation
Pa0012 20006
🇷🇺Vladimir, Russian Federation
Pa0012 20008
🇷🇺Yaroslavl, Russian Federation
Pa0012 20015
🇷🇺Yaroslavl, Russian Federation
Pa0012 40045
🇪🇸A Coruna, Spain
Pa0012 40105
🇪🇸Cordoba, Spain
Pa0012 40102
🇪🇸Málaga, Spain
Pa0012 40101
🇪🇸Sabadell, Spain
Pa0012 40104
🇪🇸Santiago de Compostela, Spain
Pa0012 40049
🇪🇸Sevilla, Spain
Pa0012 40106
🇪🇸Sevilla, Spain
Pa0012 40099
🇪🇸Vigo, Spain
Pa0012 40109
🇬🇧Oxford, United Kingdom
Pa0012 40116
🇬🇧Peterborough, United Kingdom
Pa0012 40107
🇬🇧Wolverhampton, United Kingdom